| Connect Hearing, Inc. | |
|
8950 W Olympic Blvd, Suite 207, Beverly Hills, CA 90211-3561 | |
| (310) 858-1527 | |
| (310) 858-6721 |
| Full Name | Connect Hearing, Inc. |
|---|---|
| Type | Facility |
| Speciality | Hearing Aid Equipment |
| Location | 8950 W Olympic Blvd, Beverly Hills, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386996882 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Connect Hearing, Inc. 750 N Commons Dr Ste 200, Aurora, IL 60504-7940 Ph: (630) 303-5380 | Connect Hearing, Inc. 8950 W Olympic Blvd, Suite 207, Beverly Hills, CA 90211-3561 Ph: (310) 858-1527 |
News Archive
Prof. Ming-Shaung Ju of the Department of Mechanical Engineering at National Cheng Kung University (NCKU), Tainan, Taiwan, has developed rehabilitation robots by integrating the experience of physical therapy experts at NCKU Hospital, opening a new road for stroke patients' rehabilitation.
Today, Lung Cancer Alliance-New York (LCA-NY) issued its 1st Report Card on Lung Cancer. This Report is an assessment of progress being made against lung cancer in the state of New York. LCA-NY is a chapter of Lung Cancer Alliance (LCA), the only national organization dedicated exclusively to patient support and advocacy for people living with or at risk for lung cancer.
Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that effective as of July 1, 2010 it has entered into a joint venture with Chang'An Hospital for the operation of Chang'An Hospital's cancer treatment facilities by acquiring a 52% equity interest in Xi'an Wan Jie Hua Xiang Medical Technology Development Limited.
Bobby Boyle engages in serious year-round sports training and has had his share of minor muscle injuries. When the 12-year-old athlete felt tightness in the back of his thigh while sprinting at track practice, he and his parents thought he pulled a hamstring and assumed it would heal with limited exercise time.
CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.
› Verified 7 days ago